SK Life Science, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2002-01-01
- Employees
- 101
- Market Cap
- -
Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT00697918
Efficacy of YKP3089 in Patients With Photosensitive Epilepsy
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2014-01-31
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT00616148
- Locations
- 🇺🇸
Cornell Medical Center, New York, New York, United States
🇺🇸University of Pennsylvania Epilepsy Center, Philadelphia, Pennsylvania, United States
🇺🇸Johns Hopkins Medical Center, Baltimore, Maryland, United States
Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT00563459
A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT00524056
Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT00501202
An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN).
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT00492323
A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2012-06-18
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 563
- Registration Number
- NCT00433667
A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2012-06-20
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 566
- Registration Number
- NCT00425282
Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- SK Life Science, Inc.
- Registration Number
- NCT00228969
An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 421
- Registration Number
- NCT00210522
© Copyright 2024. All Rights Reserved by MedPath